IMPACT BIOMEDICAL INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| 2025 | 2024 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Loss from continuing operations | $(11,870,000) | $(24,770,000) |
| Adjustments to reconcile loss from operations to net cash used by operating activities: | ||
| Depreciation and amortization | 1,145,000 | 1,119,000 |
| Stock based compensation | 13,000 | 19,000 |
| Issuance of shares for professional services rendered | 190,000 | |
| Accrued interest on notes payable | 793,000 | 1,065,000 |
| Change in deferred tax liability | (2,580,000) | 33,000 |
| Change in fair value of note payable, related party | 9,388,000 | (5,068,000) |
| Impairment of inventory | 419,000 | |
| Loss on disposal of fixed assets | 12,000 | - |
| Impairment of fixed assets | - | 263,000 |
| Impairment of goodwill | - | 25,093,000 |
| Decrease (increase) in assets: | ||
| Accounts receivable | (1,000) | 128,000 |
| Inventory | 7,000 | - |
| Prepaid expenses and other current assets | 126,000 | (265,000) |
| Increase (decrease) in liabilities: | ||
| Accounts payable | 470,000 | (436,000) |
| Accrued expenses | (2,000) | (35,000) |
| Net cash used operating activities | (1,890,000) | (2,854,000) |
| Cash flows from investing activities: | ||
| Payments received on notes receivable | 3,000 | 2,000 |
| Net cash provided by investing activities | 3,000 | 2,000 |
| Cash flows from financing activities: | ||
| Borrowings from related party | 184,000 | - |
| Payments to related party | (293,000) | - |
| Borrowings of note payable, related party | - | 1,124,000 |
| Issuances of common stock, net of issuance costs | - | 3,726,000 |
| Net cash (used) provided by financing activities | (109,000) | 4,850,000 |
| Net increase (decrease) in cash | (1,996,000) | 1,998,000 |
| Cash and cash equivalents at beginning of year | 1,999,000 | 1,000 |
| Cash and cash equivalents at end of year | $3,000 | $1,999,000 |
**I
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.